During a press conference Tuesday at the International AIDS Conference in Vienna, Anthony Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases at NIH, describes the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial. The study is testing the safety and efficacy of microbicide gel containing the ARV drug tenofovir, and oral tablets containing tenofovir or a combination of tenofovir and emtricitabine known by the brand name Truvada.
Living with severe depression or an anxiety disorder can have a similar impact on patients’ promptness in seeking care following an HIV diagnosis as living far […]
Study finds more than 80 percent of patients needing WHO recommended last resort treatment for drug-resistant TB not getting it
Roughly four years after the World Health Organization recommended that the newest drugs against tuberculosis be made available to patients for whom they represented a last […]
WHO report on global antibiotic resistance highlights growing threats in the face of surveillance gaps
Surveillance data from 22 countries show some of the world’s most common and potentially deadly infections gaining ground globally against the antibiotics used to treat them, […]
The idea of pairing responses to diseases found in the global south that are so neglected that they are classified by that word with the better-funded, […]